Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III Clinical Study of Evenamide (NW-3509) in Patients with Schizophrenia Experiencing Worsening of Psychosis on Atypical Antipsychotics

Next Previous
X
Search
Trial Profile

A Pivotal Phase III Clinical Study of Evenamide (NW-3509) in Patients with Schizophrenia Experiencing Worsening of Psychosis on Atypical Antipsychotics

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Newron Pharmaceuticals

    • Most Recent Events

    • 01 Apr 2021 According to a Newron Pharmaceuticals media release, the proposed phase III clinical trial program with evenamide targets patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics (CT profile 288917), and treatment-resistant patients not responding to clozapine. Clozapine is the only antipsychotic approved worldwide for treatment-resistant schizophrenia (CT profile 335685). The program will commence once study 008A results are available.
    • 16 Mar 2021 According to a Newron Pharmaceuticals media release, the company remains on track to initiate the pivotal Phase III program in Q3 2021.
    • 11 Aug 2020 According to a Newron Pharmaceuticals media release, Phase III studies with evenamide will be initiated in Q2 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top